MDS and AML, Two Distinct Disease Entities on a Continuum
Myelodysplastic neoplasms (MDS; also known as Myelodysplastic Syndromes), and acute myeloid leukemia (AML) are two related but distinct disease entities requiring differential treatment approaches. Watch this video to find out more on the biological, morphological, and clinical differences between the two diseases, and why patient-centric, tailored treatment approaches are important to manage patients with either MDS or AML.
Moh’d Khushman, MD, discusses INCA33890’s mechanism of action, phase 1 safety and efficacy data, and the design of NEXERA-303 in MSS colorectal cancer.
Nunnery and Bond discuss how patients and advocates can navigate second opinions, mental health support, and the long-term effects of cancer treatment.